Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027

Pages: 120
Geography: Global
Delivery Timeline: 24 Hours
Publication: Oct, 2018

SKU: DIMI0376

Single User License
(20% Off)
$6,250.00
$5000
Buy
Site License
(30% Off)
$12,500.00
$8750
Buy
Global License
(40% Off)
$18,750.00
$11250
Buy

Request Sample

Name*
Email ID*
Mobile*
Company*
Country*
Zip Code*
Address*
Message*

Request Sample Pages

Request Before Buy

Inquire Before Buy

Send Friend

Send to Friend

DelveInsight’s ‘Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
China

Study Period: 2016-2027

Triple Negative Breast Cancer (TNBC) - Disease Understanding and Treatment Algorithm

The DelveInsight Triple Negative Breast Cancer (TNBC) market report gives the thorough understanding of the Triple Negative Breast Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Triple Negative Breast Cancer in the US, Europe, Japan and China.

Triple Negative Breast Cancer Epidemiology

The Triple Negative Breast Cancer (TNBC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 Countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed incident cases and sub-type specific incident cases) scenario of Triple Negative Breast Cancer (TNBC) in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.

According to DelveInsight, the total number of diagnosed incident population of Triple Negative Breast Cancer (TNBC) was found to be 123,914 in the year 2016.

Triple Negative Breast Cancer Drug Chapters

This segment of the Triple Negative Breast Cancer report encloses the detailed analysis of marketed drugs and late stage (Registration, Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

At present, systemic chemotherapy remains the mainstay for the treatment of TNBC due to lack of targeted therapies and contributes towards the market size of TNBC. The several therapeutic classes of the drugs include DNA repair complex like (platinum compounds and taxanes), p53 like (taxanes), cell proliferation like (anthracycline containing regimen) and targeted therapy. Detailed chapter for upcoming therapies like Sacituzumab Govitecan (Immunomedics), Atezolizumab (Roche), Pembrolizumab (Merck), Ipatasertib (Roche), Enzalutamide (Pfizer/Astellas), Cobimetinib (Roche), Rucaparib (Clovis Oncology), Niraparib (Tesaro) and Capitasertib (AstraZeneca) have been covered in the report.

Triple Negative Breast Cancer Market Outlook

The Triple Negative Breast Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Triple Negative Breast Cancer in G8 Countries was found to be USD 0.543 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Triple Negative Breast Cancer Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Triple Negative Breast Cancer Report Insights

Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Triple Negative Breast Cancer Report Key Strengths

10 Year Forecast
G8 Countries Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Triple Negative Breast Cancer Report Assessment

Current Treatment Practices
Unmet Needs
Detailed Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Triple Negative Breast Cancer market
Organize sales and marketing efforts by identifying the best opportunities for Triple Negative Breast Cancer market
To understand the future market competition in the Triple Negative Breast Cancer market

1. Key Insights

2. Triple Negative Breast Cancer Market Overview at a Glance

2.1. Market Share (%) Distribution of Triple Negative Breast Cancer in 2016

2.2. Market Share (%) Distribution of Triple Negative Breast Cancer in 2027

3. Disease Background and Overview: Triple Negative Breast Cancer

3.1. Introduction

3.2. Types of Breast Cancer

3.3. Risk factors

3.4. Molecular Subtypes in Triple Negative Breast Cancer

3.5. Mutations Associated with Triple Negative Breast Cancer

3.6. Pathogenesis

3.7. Signs and Symptoms

3.8. Diagnosis

3.9. Diagnostic Guidelines

3.10. Stages of Triple Negative Breast Cancer

3.11. Molecular Markers for TNBC and Basal-like Breast Cancer

4. Unmet Needs

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Population and Forecast Parameters

5.3. Total Diagnosed Incident Cases of TNBC in G8 countries

6. Country Wise-Epidemiology of TNBC

6.1. The United States

6.1.1. Total Diagnosed Incident cases of TNBC in the United States

6.1.2. Subtype Specific TNBC Cases in the United States

6.1.3. Gene Mutation Specific TNBC Cases in the United States

6.1.4. Stage Specific TNBC Cases in the United States

6.2. EU5 Countries

6.3. Germany

6.3.1. Total Diagnosed Incident cases of TNBC in Germany

6.3.2. Subtype Specific TNBC Cases in Germany

6.3.3. Gene Mutation Specific TNBC Cases in Germany

6.3.4. Stage Specific TNBC Cases in Germany

6.4. France

6.4.1. Total Diagnosed Incident cases of TNBC in France

6.4.2. Subtype Specific TNBC Cases in France

6.4.3. Gene Mutation Specific TNBC Cases in France

6.4.4. Stage Specific TNBC Cases in France

6.5. Italy

6.5.1. Total Diagnosed Incident cases of TNBC in Italy

6.5.2. Subtype Specific TNBC Cases in Italy

6.5.3. Gene Mutation Specific TNBC Cases in Italy

6.5.4. Stage Specific TNBC Cases in Italy

6.6. Spain

6.6.1. Total Diagnosed Incident cases of TNBC in Spain

6.6.2. Subtype Specific TNBC Cases in Spain

6.6.3. Gene Mutation Specific TNBC Cases in Spain

6.6.4. Stage Specific TNBC Cases in Spain

6.7. United Kingdom

6.7.1. Total Diagnosed Incident cases of TNBC in the United Kingdom

6.7.2. Subtype Specific TNBC Cases in the United Kingdom

6.7.3. Gene Mutation Specific TNBC Cases in the United Kingdom

6.7.4. Stage Specific TNBC Cases in the United Kingdom

6.8. Japan

6.8.1. Total Diagnosed Incident cases of TNBC in Japan

6.8.2. Subtype Specific TNBC Cases in Japan

6.8.3. Gene Mutation Specific TNBC Cases in Japan

6.8.4. Stage Specific TNBC Cases in Japan

6.9. China

6.9.1. Total Diagnosed Incident cases of TNBC in China

6.9.2. Subtype Specific TNBC Cases in China

6.9.3. Gene Mutation Specific TNBC Cases in China

6.9.4. Stage Specific TNBC Cases in China

7. Treatment Practices

7.1. Treatment

7.2. Treatment Guidelines

8. Marketed Drug Analysis

8.1. Lynparza: AstraZeneca

8.1.1. Drug Description

8.1.2. Regulatory Milestones

8.1.3. Clinical Development

8.1.4. Safety and Efficacy

8.1.5. Product Profile

9. Emerging Therapies

9.1. Emerging Drugs Analysis

9.1.1. Sacituzumab Govitecan: Immunomedics

9.1.2. Drug Description

9.1.3. Regulatory Milestones

9.1.4. Clinical Development

9.1.5. Safety and Efficacy

9.1.6. Product Profile

9.2. Atezolizumab: Roche

9.2.1. Product Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Safety and Efficacy

9.2.5. Product Profile

9.3. Pembrolizumab: Merck

9.3.1. Drug Description

9.3.2. Other Development Activities

9.3.3. Clinical Development

9.3.4. Safety and Efficacy

9.3.5. Product Profile

9.4. Ipatasertib: Roche

9.4.1. Product Description

9.4.2. Other Development Activities

9.4.3. Clinical Development

9.4.4. Safety and Efficacy

9.4.5. Product Profile

9.5. Enzalutamide: Pfizer/Astellas

9.5.1. Product Description

9.5.2. Other Development Activities

9.5.3. Clinical Development

9.5.4. Safety and Efficacy

9.5.5. Product Profile

9.6. Cobimetinib: Hoffman La Roche

9.6.1. Product Description

9.6.2. Other Development Activities

9.6.3. Clinical Development

9.6.4. Safety and Efficacy

9.6.5. Product Profile

9.7. Rucaparib: Clovis Oncology

9.7.1. Product Description

9.7.2. Other Development Activities

9.7.3. Clinical Development

9.7.4. Safety and Efficacy

9.7.5. Product Profile

9.8. Niraparib: Tesaro

9.8.1. Product Description

9.8.2. Other Development Activities

9.8.3. Clinical Development

9.8.4. Safety and Efficacy

9.8.5. Product Profile

9.9. Capivasertib: AstraZeneca

9.9.1. Product Description

9.9.2. Clinical Development

9.9.3. Safety and Efficacy

9.9.4. Product Profile

10. Triple Negative Breast Cancer [TNBC]: G8 Countries Market Analysis

10.1. Key Findings

10.2. Total Market Size of Triple Negative Breast Cancer (TNBC) in G8 Countries

10.3. G8 Countries Market Size of TNBC by First Line of Therapies

10.4. G8 Countries Market Size of TNBC by Second Line of Therapies

11. Market Outlook by Country

11.1. The United States: Market Outlook

11.2. United States Market Size

11.2.1. Total Market size of Triple Negative Breast Cancer [TNBC]

11.2.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.2.3. Market Size by First Line of Therapies

11.2.4. Market Size by Second Line of Therapies

11.3. EU-5 Countries: Market Outlook

11.4. Germany Market Size

11.4.1. Total Market size of Triple Negative Breast Cancer

11.4.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.4.3. Market Size by First Line of Therapies

11.4.4. Market Size by Second Line of Therapies

11.5. France Market Size

11.5.1. Total Market size of Triple Negative Breast Cancer

11.5.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.5.3. Market Size by First Line of Therapies

11.5.4. Market Size by Second Line of Therapies

11.6. Italy Market Size

11.6.1. Total Market size of Triple Negative Breast Cancer

11.6.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.6.3. Market Size by First Line of Therapies

11.6.4. Market Size by Second Line of Therapies

11.7. Spain Market Size

11.7.1. Total Market size of Triple Negative Breast Cancer

11.7.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.7.3. Market Size by First Line of Therapies

11.7.4. Market Size by Second Line of Therapies

11.8. United Kingdom Market Size

11.8.1. Total Market size of Triple Negative Breast Cancer [TNBC]

11.8.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.8.3. Market Size by First Line of Therapies

11.8.4. Market Size by Second Line of Therapies

11.9. Japan: Market Outlook

11.10. Japan: Market Size

11.10.1. Total Market size of Triple Negative Breast Cancer

11.10.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.10.3. Market Size by First Line of Therapies

11.10.4. Market Size by Second Line of Therapies

11.11. China: Market Outlook

11.12. China: Market Size

11.12.1. Total Market size of Triple Negative Breast Cancer

11.12.2. Triple Negative Breast Cancer Market Size by Line of Therapies

11.12.3. Market Size by First Line of Therapies

11.12.4. Market Size by Second Line of Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

14.1. Report Methodology

14.2. Sources Used

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

Table 1: Total Incident Cases of TNBC in G8 Countries (2016-2027)

Table 2: Total Diagnosed Incident Cases of TNBC in the United States (2016-2027)

Table 3: Subtype Specific TNBC Cases in the United States (2016-2027)

Table 4: Gene Mutation Specific TNBC Cases in the United States (2016-2027)

Table 5: Stage Specific TNBC Cases in the United States (2016-2027)

Table 6: Total Diagnosed Incident cases of TNBC in Germany (2016-2027)

Table 7: Subtype Specific TNBC Cases in Germany (2016-2027)

Table 8: Gene Mutation Specific TNBC Cases in Germany (2016-2027)

Table 9: Stage Specific TNBC Cases in Germany (2016-2027)

Table 10: Total Diagnosed Incident cases of TNBC in France (2016-2027)

Table 11: Subtype Specific TNBC Cases in France (2016-2027)

Table 12: Gene Mutation Specific TNBC Cases in France (2016-2027)

Table 13: Stage Specific TNBC Cases in France (2016-2027)

Table 14: Total Diagnosed Incident cases of TNBC in Italy (2016-2027)

Table 15: Subtype Specific TNBC Cases in Italy (2016-2027)

Table 16: Gene Mutation Specific TNBC Cases in Italy (2016-2027)

Table 17: Stage Specific TNBC Cases in Italy (2016-2027)

Table 18: Total Diagnosed Incident cases of TNBC in Spain (2016-2027)

Table 19: Subtype Specific TNBC Cases in Spain (2016-2027)

Table 20: Gene Mutation Specific TNBC Cases in Spain (2016-2027)

Table 21: Stage Specific TNBC Cases in Spain (2016-2027)

Table 22: Total Diagnosed Incident Cases of TNBC in the United Kingdom (2016-2027)

Table 23: Subtype Specific TNBC Cases in the United Kingdom (2016-2027)

Table 24: Gene Mutation Specific TNBC Cases in the United Kingdom (2016-2027)

Table 25: Stage Specific TNBC Cases in the United Kingdom (2016-2027)

Table 26: Total Diagnosed Incident cases of TNBC in Japan (2016-2027)

Table 27: Subtype Specific TNBC Cases in Japan (2016-2027)

Table 28: Gene Mutation Specific TNBC Cases in Japan (2016-2027)

Table 29: Stage Specific TNBC Cases in Japan (2016-2027)

Table 30: Total Diagnosed Incident cases of TNBC in China (2016-2027)

Table 31: Subtype Specific TNBC Cases in China (2016-2027)

Table 32: Gene Mutation Specific TNBC Cases in China (2016-2027)

Table 33: Stage Specific TNBC Cases in China (2016-2027)

Table 34: Lynparza, Clinical Trial Description, 2018

Table 35: Emerging Drugs Analysis – Registration and Phase III

Table 36: Emerging Drugs Analysis – Phase II

Table 37: Sacituzumab govitecan, Clinical Trial Description, 2018

Table 38:Atezolizumab, Clinical Trial Description, 2018

Table 39: Pembrolizumab, Clinical Trial Description, 2018

Table 40: Ipatasertib, Clinical Trial Description, 2018

Table 41: Enzalutamide, Clinical Trial Description, 2018

Table 42: Cobimetinib, Clinical Trial Description, 2018

Table 43: Rucaparib, Clinical Trial Description, 2018

Table 44: Rucaparib, Clinical Trial Description, 2018

Table 45: Capivasertib, Clinical Trial Description, 2018

Table 46: G8 Countries Market Size of TNBC in USD Billion (2016-2027)

Table 47: G8 Countries Market Size of TNBC by First Line of Therapies in USD Billion (2016-2027)

Table 48: G8 Countries Market Size of TNBC by Second Line of Therapies in USD Billion (2016-2027)

Table 49: The US Market Triple Negative Breast Cancer in USD Billion (2016-2027)

Table 50: The U.S. TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 51: The US TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 52: The US TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 53: Germany Market Triple Negative Breast Cancer in USD Billion(2016-2027)

Table 54: Germany TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 55: Germany TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 56: Germany TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 57: France Market Triple Negative Breast Cancer in USD Billion(2016-2027)

Table 58: France TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 59: France TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 60: France TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 61: Italy Market Triple Negative Breast Cancer in USD Billion (2016-2027)

Table 62: Italy TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 63: Italy TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 64: Italy TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 65: Spain Market Triple Negative Breast Cancer in USD Billion (2016-2027)

Table 66: Spain TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 67: Spain TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 68: Spain TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 69: The UK Market Triple Negative Breast Cancer in USD Billion (2016-2027)

Table 70: The UK TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 71: The UK TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 72: The UK TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 73: Japan Market Triple Negative Breast Cancer in USD Billion (2016-2027)

Table 74: Japan TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 75: Japan TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 76: Japan TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Table 77: China Market Triple Negative Breast Cancer in USD Billion (2016-2027)

Table 78: China TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Table 79: China TNBC market size by First Line of Therapies in USD Billion (2016-2027)

Table 80: China TNBC market size by Second Line of Therapies in USD Billion (2016-2027)

Figure 1: Molecular Phenotypes of Triple Negative Breast Cancer

Figure 2: Molecular Phenotypes of Triple Negative Breast Cancer

Figure 3: Diagnostic guidelines for TNBC: Immunohistochemistry (IHC)

Figure 4: Diagnostic guidelines for TNBC: Immunohistochemistry (IHC)

Figure 5: Unmet Needs for Triple Negative Breast Cancer

Figure 6: Total Diagnosed Incident Cases of TNBC in G8 Countries (2016-2027)

Figure 7: Total Diagnosed Incident Cases of TNBC in the United States (2016-2027)

Figure 8: Subtype Specific TNBC Cases in the United States (2016-2027)

Figure 9: Gene Mutation Specific TNBC Cases in the United States (2016-2027)

Figure 10: Stage Specific TNBC Cases in the United States (2016-2027)

Figure 11: Total Diagnosed Incident cases of TNBC in Germany (2016-2027)

Figure 12: Subtype Specific TNBC Cases in Germany (2016-2027)

Figure 13: Gene Mutation Specific TNBC Cases in Germany (2016-2027)

Figure 14: Stage Specific TNBC Cases in Germany (2016-2027)

Figure 15: Total Diagnosed Incident cases of TNBC in France (2016-2027)

Figure 16: Subtype Specific TNBC Cases in France (2016-2027)

Figure 17: Gene Mutation Specific TNBC Cases in France (2016-2027)

Figure 18: Stage Specific TNBC Cases in France (2016-2027)

Figure 19: Total Diagnosed Incident cases of TNBC in Italy (2016-2027)

Figure 20: Subtype Specific TNBC Cases in Italy (2016-2027)

Figure 21: Gene Mutation Specific TNBC Cases in Italy (2016-2027)

Figure 22: Stage Specific TNBC Cases in Italy (2016-2027)

Figure 23: Total Diagnosed Incident cases of TNBC in Spain (2016-2027)

Figure 24: Subtype Specific TNBC Cases in Spain (2016-2027)

Figure 25: Gene Mutation Specific TNBC Cases in Spain (2016-2027)

Figure 26: Stage Specific TNBC Cases in Spain (2016-2027)

Figure 27: Total Diagnosed Incident Cases of TNBC in the United Kingdom (2016-2027)

Figure28: Subtype Specific TNBC Cases in the United Kingdom (2016-2027)

Figure 29: Gene Mutation Specific TNBC Cases in the United Kingdom (2016-2027)

Figure 30: Stage Specific TNBC Cases in the United Kingdom (2016-2027)

Figure 31: Total Diagnosed Incident cases of TNBC in Japan (2016-2027)

Figure 32: Subtype Specific TNBC Cases in Japan (2016-2027)

Figure 33: Gene Mutation Specific TNBC Cases in Japan (2016-2027)

Figure 34: Stage Specific TNBC Cases in Japan (2016-2027)

Figure 35: Total Diagnosed Incident cases of TNBC in China (2016-2027)

Figure 36: Subtype Specific TNBC Cases in China (2016-2027)

Figure 37: Gene Mutation Specific TNBC Cases in China (2016-2027)

Figure 38: Stage Specific TNBC Cases in China (2016-2027)

Figure 39: G8 Countries Market Size of TNBC in USD Billion (2016-2027)

Figure 40: G8 Countries Market Size of TNBC by First Line of Therapies in USD Billion (2016-2027)

Figure 41: G8 Countries Market Size of TNBC by Second Line of Therapies in USD Billion (2016-2027)

Figure 42: Market Size of TNBC in the United States, USD Billion (2016-2027)

Figure 43: The U.S. TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 44: The U.S. market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 45: The U.S. market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 46: Market Size of TNBC in the Germany, USD Billion (2016-2027)

Figure 47: Germany TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 48: Germany market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 49: Germany market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 50: Market Size of TNBC in France, USD Billion (2016-2027)

Figure 51: France TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 52: France market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 53: The France market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 54: Market Size of TNBC in Italy, USD Billion (2016-2027)

Figure 55: Italy TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 56: Italy market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 57: Italy market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 58: Market Size of TNBC in Spain, USD Billion (2016-2027)

Figure 59: Spain TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 60: Spain market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 61: Spain market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 62: Market Size of TNBC in the United Kingdom, USD Billion (2016-2027)

Figure 63: The US TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 64: The UK market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 65: The UK market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 66: Market Size of TNBC in Japan, USD Billion (2016-2027)

Figure 67: The Japan TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 68: Japan market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 69: Japan market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 70: Market Size of TNBC in China, USD Billion (2016-2027)

Figure 71: The China TNBC Market Size by Line of therapies in USD Billion (2016-2027)

Figure 72: China market size of TNBC by First Line of therapies in USD Billion (2016-2027)

Figure 73: China market size of TNBC by Second Line of therapies in USD Billion (2016-2027)

Figure 74:Market Drivers for Triple Negative Breast Cancer

Figure 75: Market Barriers for Triple Negative Breast Cancer